PTC Therapeutics Inc (PTCT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
PTC Therapeutics Inc stock (PTCT) is currently trading at $66.75. PTC Therapeutics Inc PE ratio is 7.52. PTC Therapeutics Inc PS ratio (Price-to-Sales) is 3.09. Analyst consensus price target for PTCT is $87.57. WallStSmart rates PTCT as Sell.
- PTCT PE ratio analysis and historical PE chart
- PTCT PS ratio (Price-to-Sales) history and trend
- PTCT intrinsic value — DCF, Graham Number, EPV models
- PTCT stock price prediction 2025 2026 2027 2028 2029 2030
- PTCT fair value vs current price
- PTCT insider transactions and insider buying
- Is PTCT undervalued or overvalued?
- PTC Therapeutics Inc financial analysis — revenue, earnings, cash flow
- PTCT Piotroski F-Score and Altman Z-Score
- PTCT analyst price target and Smart Rating
PTC Therapeutics Inc
📊 No data available
Try selecting a different time range
PTCT Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · PTC Therapeutics Inc (PTCT)
PTCT trades 22% above its Graham fair value of $58.34, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
PTC Therapeutics Inc (PTCT) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, profit margin, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
PTC Therapeutics Inc (PTCT) Key Strengths (4)
Growing significantly faster than its price suggests
Keeps $39 of every $100 in revenue as net profit
113.42% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
PTC Therapeutics Inc (PTCT) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -22.70%, a shrinking business
Very expensive at 1743.3x book value
Revenue is fairly priced at 3.09x sales
Supporting Valuation Data
PTC Therapeutics Inc (PTCT) Detailed Analysis Report
Overall Assessment
This company scores 43/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 4 register as strengths (avg 9.3/10) while 5 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Profit Margin, Institutional Own.. Valuation metrics including PEG Ratio (0.81) suggest the stock is attractively priced. Profitability is solid with Profit Margin at 39.40%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (3.09), Price/Book (1743.27) suggest expensive pricing. Growth concerns include Revenue Growth at -22.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -7740.00%, Operating Margin at -49.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -7740.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -22.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PTCT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PTCT's Price-to-Sales ratio of 3.09x sits near its historical average of 3.14x (29th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 6% below its historical high of 3.27x set in Mar 2026, and 2% above its historical low of 3.03x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for PTC Therapeutics Inc (PTCT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
PTC Therapeutics Inc faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 1.7B with 23% decline year-over-year. Profit margins are strong at 39.4%, reflecting pricing power and operational efficiency.
Key Findings
Revenue contracted 23% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -37M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact PTC Therapeutics Inc.
Bottom Line
PTC Therapeutics Inc faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About PTC Therapeutics Inc(PTCT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is headquartered in South Plainfield, New Jersey.